Author

C. Janneke van der Woude

Mistakes in series ... IBD and reproduction
Mistakes in series ... IBD and reproduction

C. Janneke van der Woude  et al.

Pregnancy in IBD
Pregnancy in IBD

C. Janneke van der Woude  et al.

Mistakes in pregnancy and IBD
Mistakes in pregnancy and IBD

C. Janneke van der Woude

The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease
The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease

C. Janneke van der Woude  et al.

DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE
DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE

C. Janneke van der Woude  et al.

PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?
PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?

C. Janneke van der Woude  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations

C. Janneke van der Woude  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

C. Janneke van der Woude  et al.

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL
COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

C. Janneke van der Woude  et al.

CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL
CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL

C. Janneke van der Woude  et al.

Item 1 - 10 / 10
1